Abstract:Clopidogrel is the most widely used P2Y12-inhibitor in Chinese patients with acute coronary syndrome (ACS). It was previously found that carriers with two CYP2C19 loss-of-function (LOF) alleles, but not one LOF allele, had poorer clinical outcomes. The current study further determined the link between CYP2C19 genotype status and clopidogrel response, using P2Y12-Gi dependent signaling endpoints and mean platelet volume (MPV). A total of 196 patients with ACS were included. CYP2C19 variant alleles were detected by gene sequencing. Platelet reactivity was assessed using thrombelastographs at 24 hours after 300 mg clopidogrel loading. P2Y12-Gi signaling was simultaneously measured using flow cytometric analysis of vasodilator-stimulated phosphoprotein phosphorylationplatelet reactivity (VASP-PRI) and Akt phosphorylation (P-Akt) indexes. Measurements of hematological parameters were carried out before and after one month of treatment with 75 mg clopidogrel. It was found that increases in VASP-PRI positively correlated with the number of LOF, significantly. However, only two LOF carriers showed a higher P-Akt index after clopidogrel treatment. VASP-PRI was positively associated with platelet aggregation (R = 0.661, P < 0.001), but not with P-Akt index. MPV was larger in patients with two LOFs after clopidogrel treatment. Results indicate that only two CYP2C19 LOF carriers had a more active state of P2Y12-Gi signaling and larger MPV in postclopidogrel platelets.

Chinese patients carrying two CYP 2 C 19 LOFs have a more active state of P 2 Y 12-Gi signaling and larger MPV in post-clopidogrel platelets with acute coronary syndrome